QBX258
PreclinicalSmall molecule
NovartisQBX258 is one of 30 small molecule programs targeting Breast Cancer. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Tianeptine
PfizerPreclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
4SCAR T Cells
SShenzhen Geno-Immune Medical Institute
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QBX258. EMBL-EBI & Wellcome Sanger Institute.
- [4]